Table 4.
Adverse events of combination therapy.
| All (N = 33) |
SOR/NIVO (N = 8) |
SOR/PEMBRO (N = 4) |
LEN/NIVO (N = 11) |
LEN/PEMBRO (N = 10) |
p-Value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | N | % | ||
| HFRS | 10 | (30.3%) | 4 | (50.0%) | 2 | (50.0%) | 1 | (16.7%) | 3 | (30.0%) | 0.208 |
| Hypertension | 6 | (18.2%) | 0 | 0 | 2 | (18.2%) | 4 | (40.0%) | 0.118 | ||
| Diarrhea | 10 | (30.3%) | 2 | (25.0%) | 2 | (50.0%) | 3 | (27.3%) | 3 | (30.0%) | 0.828 |
| Fatigue | 12 | (36.4%) | 2 | (25.0%) | 2 | (50.0%) | 5 | (45.5%) | 3 | (30.0%) | 0.721 |
All p-values were analyzed with Pearson’s Chi-square test. Abbreviations: HFRS, hand foot syndrome reaction; LEN, lenvatinib; N, number of patients. NIVO, nivolumab; PEMBRO, pembrolizumab; SOR, sorafenib.